The Léon Bérard Cancer Center will be the promoter of an open-label phase I/II study conducted according to a Fleming design, investigating the safety and efficacy of 177Lu-PSMA-I&T repeated cycles in patients with metastatic ccRCC. This evidence concerns the gene FOLH1 and nonpapillary renal cell carcinoma.